jueves, 12 de junio de 2014

Menos mal que...vamos mal (XXV): Invertir en "farmacéuticas"









Ver



  
Pongamos, por ejemplo...que hablo de AZ...

 3-Year Investment In AstraZeneca PLC Returns 17% Per Year



The Defensive Value Portfolio’s investment in AstraZeneca PLC has been an almost textbook example of how a strong, market-leading company can survive through tough times, and how patient and brave investors can sometimes get lucky.



Ver anterior:

Menos mal que...vamos mal (XXIV), Annual Pharmaceutical Industry Audit: Enterprise Value

Publicar un comentario en la entrada